Logo image of BCAX

BICARA THERAPEUTICS INC (BCAX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BCAX - US0554771032 - Common Stock

16.38 USD
-0.34 (-2.03%)
Last: 1/21/2026, 11:33:01 AM
Fundamental Rating

3

Overall BCAX gets a fundamental rating of 3 out of 10. We evaluated BCAX against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BCAX as it has an excellent financial health rating, but there are worries on the profitability. BCAX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year BCAX has reported negative net income.
  • BCAX had a negative operating cash flow in the past year.
BCAX Yearly Net Income VS EBIT VS OCF VS FCFBCAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of BCAX (-28.61%) is better than 68.38% of its industry peers.
  • The Return On Equity of BCAX (-30.17%) is better than 76.19% of its industry peers.
Industry RankSector Rank
ROA -28.61%
ROE -30.17%
ROIC N/A
ROA(3y)-200.05%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCAX Yearly ROA, ROE, ROICBCAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • BCAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAX Yearly Profit, Operating, Gross MarginsBCAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

  • BCAX has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for BCAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCAX Yearly Shares OutstandingBCAX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
BCAX Yearly Total Debt VS Total AssetsBCAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • BCAX has an Altman-Z score of 23.71. This indicates that BCAX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of BCAX (23.71) is better than 90.48% of its industry peers.
  • There is no outstanding debt for BCAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.71
ROIC/WACCN/A
WACCN/A
BCAX Yearly LT Debt VS Equity VS FCFBCAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • BCAX has a Current Ratio of 14.14. This indicates that BCAX is financially healthy and has no problem in meeting its short term obligations.
  • BCAX's Current ratio of 14.14 is amongst the best of the industry. BCAX outperforms 90.48% of its industry peers.
  • A Quick Ratio of 14.14 indicates that BCAX has no problem at all paying its short term obligations.
  • The Quick ratio of BCAX (14.14) is better than 90.48% of its industry peers.
Industry RankSector Rank
Current Ratio 14.14
Quick Ratio 14.14
BCAX Yearly Current Assets VS Current LiabilitesBCAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

  • BCAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -302.87%.
EPS 1Y (TTM)-302.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BCAX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.42% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.44%
EPS Next 2Y-8.15%
EPS Next 3Y-4.55%
EPS Next 5Y0.42%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCAX Yearly Revenue VS EstimatesBCAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
BCAX Yearly EPS VS EstimatesBCAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • BCAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAX Price Earnings VS Forward Price EarningsBCAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAX Per share dataBCAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • BCAX's earnings are expected to decrease with -4.55% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.15%
EPS Next 3Y-4.55%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for BCAX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BICARA THERAPEUTICS INC

NASDAQ:BCAX (1/21/2026, 11:33:01 AM)

16.38

-0.34 (-2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-24
Inst Owners86.34%
Inst Owner Change0.01%
Ins Owners1.53%
Ins Owner Change5.23%
Market Cap897.30M
Revenue(TTM)N/A
Net Income(TTM)-121.52M
Analysts81.25
Price Target31.05 (89.56%)
Short Float %20.28%
Short Ratio14.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.91%
Min EPS beat(2)-19.6%
Max EPS beat(2)13.77%
EPS beat(4)1
Avg EPS beat(4)-21.18%
Min EPS beat(4)-60.69%
Max EPS beat(4)13.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.53%
PT rev (3m)-3.13%
EPS NQ rev (1m)1.64%
EPS NQ rev (3m)-17.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.23
P/tB 2.23
EV/EBITDA N/A
EPS(TTM)-2.24
EYN/A
EPS(NY)-3.1
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.06
OCFYN/A
SpS0
BVpS7.35
TBVpS7.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.61%
ROE -30.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-200.05%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 106.49%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.14
Quick Ratio 14.14
Altman-Z 23.71
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1710.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-302.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.13%
EPS Next Y3.44%
EPS Next 2Y-8.15%
EPS Next 3Y-4.55%
EPS Next 5Y0.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-106.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-93.65%
EBIT Next 3Y-38.39%
EBIT Next 5YN/A
FCF growth 1Y-61.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.83%
OCF growth 3YN/A
OCF growth 5YN/A

BICARA THERAPEUTICS INC / BCAX FAQ

What is the ChartMill fundamental rating of BICARA THERAPEUTICS INC (BCAX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BCAX.


What is the valuation status of BICARA THERAPEUTICS INC (BCAX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BICARA THERAPEUTICS INC (BCAX). This can be considered as Overvalued.


What is the profitability of BCAX stock?

BICARA THERAPEUTICS INC (BCAX) has a profitability rating of 1 / 10.


How financially healthy is BICARA THERAPEUTICS INC?

The financial health rating of BICARA THERAPEUTICS INC (BCAX) is 8 / 10.